UK markets close in 6 hours 50 minutes

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
58.49-0.51 (-0.86%)
At close: 04:00PM EDT
60.00 +1.51 (+2.58%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close59.00
Open59.36
Bid58.41 x 100
Ask58.62 x 100
Day's range57.66 - 59.36
52-week range19.83 - 94.75
Volume1,035,391
Avg. volume1,571,227
Market cap7.053B
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

    WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team,” said Caroline Baumal, M.D., Chief Medical Officer, Apellis. “P

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of March 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Li

  • GlobeNewswire

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

    Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 Topline data from Phase 3 VALIANT study of systemic pegcetacoplan in C3G and IC-MPGN expected in mid-2024Cash and cash equivalents of $351 million as of December 31, 2023 WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceut